Company intelligence / Profile preview

L&L Biopharmaceutical

Wuhan, Hubei, China

Ownership: Private
Development stage: Other

Overview

L&L Biopharmaceutical is a clinical-stage biotechnology company based in Wuhan, China, specializing in the discovery and development of small molecule precision medicines for oncology and metabolic diseases. The company focuses on multi-target kinase inhibitors designed to overcome resistance in various solid tumors and hematological malignancies. Its lead candidate, LL-485, is a potent multi-kinase inhibitor targeting FGFR, VEGFR, and PDGFR, currently undergoing clinical evaluation for advanced solid tumors. L&L Biopharmaceutical leverages its internal R&D capabilities to advance a pipeline of targeted therapies aimed at addressing significant unmet medical needs in the global pharmaceutical market.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on L&L Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L&L Biopharmaceutical.

Explore the full profile